Hepcidin is elevated in primary and secondary myelofibrosis and remains elevated in patients treated with ruxolitinib

Amy Zhou; Tim Kong; Jared S. Fowles; Chun Ling Jung; Maggie J. Allen; Daniel A.C. Fisher; Mary Fulbright; Elizabeta Nemeth; Tomas Ganz; Stephen T. Oh

doi:10.1111/bjh.18044

Hepcidin is elevated in primary and secondary myelofibrosis and remains elevated in patients treated with ruxolitinib

Amy Zhou, Tim Kong, Jared S. Fowles, Chun Ling Jung, Maggie J. Allen, Daniel A.C. Fisher, Mary Fulbright, Elizabeta Nemeth, Tomas Ganz, Stephen T. Oh

Research output: Contribution to journal › Letter › peer-review

11 Scopus citations

Original language	English
Pages (from-to)	e49-e52
Journal	British Journal of Haematology
Volume	197
Issue number	4
DOIs	https://doi.org/10.1111/bjh.18044
State	Published - May 2022

Access to Document

10.1111/bjh.18044

Cite this

@article{22cf480eae154ec18c11a5a490a2fc35,

title = "Hepcidin is elevated in primary and secondary myelofibrosis and remains elevated in patients treated with ruxolitinib",

author = "Amy Zhou and Tim Kong and Fowles, {Jared S.} and Jung, {Chun Ling} and Allen, {Maggie J.} and Fisher, {Daniel A.C.} and Mary Fulbright and Elizabeta Nemeth and Tomas Ganz and Oh, {Stephen T.}",

note = "Funding Information: This work was supported by NIH grants R01HL134952 (Stephen T. Oh) and T32HL007088 (Jared S. Fowles). Support for patient sample collection and processing was provided by NIH grant P01CA101937. CRP and Iron studies were run by the Core Laboratory for Clinical Studies (CLCS) at Washington University in St. Louis which is supported in part by the Washington University Diabetes Research and Training Centre (DRTC) and the Washington University Institute of Clinical and Translational Sciences (ICTS). Technical support was provided by the Alvin J. Siteman Cancer Centre Tissue Procurement Core Facility and Immunomonitoring Laboratory, which are supported by NCI Cancer Centre Support Grant P30CA91842. The Immunomonitoring Laboratory is also supported by the Andrew M and Jane M Bursky Centre for Human Immunology and Immunotherapy Programs. The authors thank D. Bender for assistance with multiplex cytokine measurement.",

year = "2022",

month = may,

doi = "10.1111/bjh.18044",

language = "English",

volume = "197",

pages = "e49--e52",

journal = "British Journal of Haematology",

issn = "0007-1048",

number = "4",

}

TY - JOUR

T1 - Hepcidin is elevated in primary and secondary myelofibrosis and remains elevated in patients treated with ruxolitinib

AU - Zhou, Amy

AU - Kong, Tim

AU - Fowles, Jared S.

AU - Jung, Chun Ling

AU - Allen, Maggie J.

AU - Fisher, Daniel A.C.

AU - Fulbright, Mary

AU - Nemeth, Elizabeta

AU - Ganz, Tomas

AU - Oh, Stephen T.

N1 - Funding Information: This work was supported by NIH grants R01HL134952 (Stephen T. Oh) and T32HL007088 (Jared S. Fowles). Support for patient sample collection and processing was provided by NIH grant P01CA101937. CRP and Iron studies were run by the Core Laboratory for Clinical Studies (CLCS) at Washington University in St. Louis which is supported in part by the Washington University Diabetes Research and Training Centre (DRTC) and the Washington University Institute of Clinical and Translational Sciences (ICTS). Technical support was provided by the Alvin J. Siteman Cancer Centre Tissue Procurement Core Facility and Immunomonitoring Laboratory, which are supported by NCI Cancer Centre Support Grant P30CA91842. The Immunomonitoring Laboratory is also supported by the Andrew M and Jane M Bursky Centre for Human Immunology and Immunotherapy Programs. The authors thank D. Bender for assistance with multiplex cytokine measurement.

PY - 2022/5

Y1 - 2022/5

UR - http://www.scopus.com/inward/record.url?scp=85124481137&partnerID=8YFLogxK

U2 - 10.1111/bjh.18044

DO - 10.1111/bjh.18044

M3 - Letter

C2 - 35128632

AN - SCOPUS:85124481137

SN - 0007-1048

VL - 197

SP - e49-e52

JO - British Journal of Haematology

JF - British Journal of Haematology

IS - 4

ER -

Hepcidin is elevated in primary and secondary myelofibrosis and remains elevated in patients treated with ruxolitinib

Access to Document

Other files and links

Cite this